title: Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma.
authors.affiliation: Department of Radiation Oncology, University Hospital of Erlangen, Germany. gerd.grabenbauer@strahlen.med.uni-erlangen.de
authors.forename: G G
authors.initials: GG
authors.lastname: Grabenbauer
authors.forename: M
authors.initials: M
authors.lastname: Buchfelder
authors.forename: U
authors.initials: U
authors.lastname: Schrell
authors.forename: R
authors.initials: R
authors.lastname: Fahlbusch
authors.forename: R
authors.initials: R
authors.lastname: Sauer
authors.forename: H J
authors.initials: HJ
authors.lastname: Staab
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D020266:Radiotherapy, Conformal; D019772:Topotecan / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan